HealthDay on MSN16h
Baseline Characteristics ID Risk for Recurrent Endoscopic Sinus SurgeryA few baseline characteristics can predict the need for recurrent endoscopic sinus surgery (ESS) among patients with chronic ...
Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...
According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...
The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for ...
Zacks.com on MSN4h
Insmed's NDA for Lung Disease Drug Gets FDA's Priority ReviewThe FDA accepts and grants priority review to INSM's NDA for brensocatib to treat patients with non-cystic fibrosis bronchiectasis. A decision is due on Aug. 12, 2025.
Insmed's promising drug pipeline includes Brensocatib and Arikayce. See why INSM stock is a strong pick with multi-billion ...
Flu season is here with some other ickiness joining the petri dish party, including allergies, strep, pneumonia, COVID-19 and norovirus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback